FDA Has Not Scheduled 7-OH: What the 2026 Federal Status Means for Patients

Why it matters

Millions of Americans using 7-hydroxymitragynine (7-OH) products need to know their federal legal standing — and the answer as of June 2026 is that no federal ban exists, even as state-by-state restrictions rapidly multiply.

The big picture

The FDA formally recommended 7-OH be placed on Schedule I on July 29, 2025, but the DEA has not yet acted on that recommendation. The result is a legal patchwork: 7-OH remains federally unscheduled while several states have moved to ban it outright. Federal scheduling, when it occurs, would make manufacture, sale, and possession illegal under federal law — dramatically changing the landscape for users and vendors.

Key findings

• As of June 13, 2026, 7-hydroxymitragynine is NOT a controlled substance under the federal Controlled Substances Act
• The FDA recommended Schedule I classification to the DEA in July 2025, but the DEA has not published a proposed rule
• Several states have banned 7-OH under their own kratom statutes, creating a fragmented regulatory environment
• Products marketed with unapproved drug claims have received FDA warning letters
• Patients using 7-OH products should monitor both federal and state-level regulatory developments closely

What they say

Restoration Recovery, an outpatient addiction clinic tracking the issue for its patients, notes: "Supply disruption — whether from a federal schedule or a state-level ban — affects whether patients can safely taper or need to transition to treatment."

Bottom line

7-OH is not federally banned as of June 2026, but the FDA recommendation for Schedule I is pending DEA action — and the regulatory window could close at any time.